ZIG BC 011619 (ZIG) | |||
---|---|---|---|
Title | Comparative Oncology Program | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Leblanc, Amy | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $539,097 | Project Dates | 01/01/2014 - 00/00/0000 |
Fiscal Year | 2015 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Chemotherapy (10.0%) Childhood Cancers (30.0%) Gene Therapy (10.0%) Gene Therapy Clinical Trials (10.0%) Interferon (5.0%) Metastasis (30.0%) Nuclear Magnetic Resonance Imaging (NMR) (10.0%) |
Brain (25.0%) Head and Neck (10.0%) Nervous System (25.0%) Non Hodgkins Lymphoma (10.0%) Sarcoma (30.0%) Buccal Cavity (10.0%) |
||
Research Type | |||
Systemic Therapies - Discovery and Development Application of Model Systems |
|||
Abstract | |||
1. Develop essential reagent kit for the study of comparative models in translational and biology-based research. Specific reagents/resources include: COTC Pharmacodynamic Core: This multidisciplinary effort operates as a laboratory with ""virtual walls"" consisting of services provided by investigators who have competed for the opportunity to contribute to the assay/procedure service catalog of the Core. The COTC PD Core is meant to facilitate early discussions with COTC trial sponsors (pharmaceutical companies) by providing the infrastructure for rapid implementation of preclinical studies needed to initiate a COTC study and then seamlessly support the clinical pharmacodynamic and biological endpoints of COTC trials. Since its inception the COTC PD Core has been used to support 6 of 12 COTC trials. The COTC PD Core completed its 3rd RFP. Canine oligonucleotide microarray: Optimized techniques and normal tissue expression standards for both a first generation and more recently a second generation canine oligonucleotide microarray have been completed and initiated. This microarray is currently available through Affymetrix. In FY 2011-12: 1) Manuscript to characterize the gene signatures of 10 normal canine tissues in collaboration with Dr. Javed Khan's Oncogenomics Section, and establish a database available for public search was completed. PLoS One. 2011;6(5):e17107. Epub 2011 May 31. Serum proteomics (SELDI-TOFF): Conditions for canine serum proteomic analysis have been optimized in collaboration with Timothy Veenstra (Biological Proteomics Program). Validated antibody data base: A database of validated antibodies for use in canine tissues is being developed within the Comparative Oncology Program in collaboration with commercial antibody vendors and Dr. David Goldsmith and is available to the public (http://ccr.cancer.gov/resources/cop/scientists/resource_antibody.asp) (Center for Cancer Research). Canine Comparative Oncology Genomics Consortium (CCOGC): Using its neutral position, the Comparative Oncology Program has brought together a broad representation of parties (academic, industry, government) focused on the genetics and biology of cancer in dogs. The shared interests of the CCOGC will result in further genomics reagent/resource development and collaborative efforts that will characterize canine cancers as molecular models of human disease. In 2007, the CCOGC launched the Pfizer-Canine Comparative Oncology and Genomics Consortium Biospecimen Repository. Canine Cancer Biospecimen Repository: A biospecimen repository of frozen, and formalin fixed tissues from 1800 dogs with cancer has been established through a contract with Fisher Bioservices. In 2013 the CCOGC began releasing tissues based on scientific merit. To date over 1000 samples have been released. Canine Cancer Tissue Arrays: In collaboration with Dr. Stephen Hewitt (CCR - Tissue Array Project), a number of robust canine cancer tissue arrays have been developed. These arrays include outcome linked canine lymphoma, outcome linked canine osteosarcoma, outcome linked nasal carcinoma, and a multi-tumor canine tissue array. Version 2.0 of the multi-tumor canine tissue array is under development. These array reagents have and will be useful for the identification of therapeutic targets in canine cancers, and the study of cancer and metastasis biology/and are used to assist with pre-clinical studies for future COTC efforts. 2. Develop multi-center collaborative network with extramural comparative oncology programs. Within this network design, implement and manage pre-clinical trials involving pet animals that will evaluate novel therapeutic strategies for cancer; Comparative Oncology Trial Consortium: The Comparative Oncology Program has used its neutral leadership position to bring together twenty top-notch schools of veterinary medicine to collaborate as a multi-center clinical trial network. This network works together through the leadership of the Comparative Onco |